Central Nervous System Stimulants Limit Caffeine Transport at the Blood-Cerebrospinal Fluid Barrier.
4-Aminopyridine
/ pharmacology
Autopsy
Biological Transport
Blood-Brain Barrier
/ chemistry
Caffeine
/ pharmacokinetics
Case-Control Studies
Cells, Cultured
Central Nervous System Stimulants
/ pharmacology
Cerebrospinal Fluid
/ chemistry
Choroid Plexus
/ chemistry
Endothelial Cells
/ chemistry
Endothelium, Vascular
/ chemistry
Humans
Models, Biological
BCSFB model
GC/MS
blood–cerebrospinal fluid barrier (BCSFB)
caffeine
choroid plexus
stimulants
vacuolation
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
07 Feb 2022
07 Feb 2022
Historique:
received:
05
01
2022
revised:
03
02
2022
accepted:
04
02
2022
entrez:
15
2
2022
pubmed:
16
2
2022
medline:
8
3
2022
Statut:
epublish
Résumé
Caffeine, a common ingredient in energy drinks, crosses the blood-brain barrier easily, but the kinetics of caffeine across the blood-cerebrospinal fluid barrier (BCSFB) has not been investigated. Therefore, 127 autopsy cases (Group A, 30 patients, stimulant-detected group; and Group B, 97 patients, no stimulant detected group) were examined. In addition, a BCSFB model was constructed using human vascular endothelial cells and human choroid plexus epithelial cells separated by a filter, and the kinetics of caffeine in the BCSFB and the effects of 4-aminopyridine (4-AP), a neuroexcitatory agent, were studied. Caffeine concentrations in right heart blood (Rs) and cerebrospinal fluid (CSF) were compared in the autopsy cases: caffeine concentrations were higher in Rs than CSF in Group A compared to Group B. In the BCSFB model, caffeine and 4-AP were added to the upper layer, and the concentration in the lower layer of choroid plexus epithelial cells was measured. The CSF caffeine concentration was suppressed, depending on the 4-AP concentration. Histomorphological examination suggested that choroid plexus epithelial cells were involved in inhibiting the efflux of caffeine to the CSF. Thus, the simultaneous presence of stimulants and caffeine inhibits caffeine transfer across the BCSFB.
Identifiants
pubmed: 35163784
pii: ijms23031862
doi: 10.3390/ijms23031862
pmc: PMC8836437
pii:
doi:
Substances chimiques
Central Nervous System Stimulants
0
Caffeine
3G6A5W338E
4-Aminopyridine
BH3B64OKL9
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
J Neurosci. 2002 Aug 1;22(15):6321-4
pubmed: 12151508
Neurosci Lett. 2008 Feb 20;432(2):146-50
pubmed: 18201823
Toxicol Appl Pharmacol. 1986 Jun 15;84(1):125-48
pubmed: 3715860
Toxicol Appl Pharmacol. 2005 Apr 1;204(1):57-68
pubmed: 15781294
FASEB J. 2006 Mar;20(3):571-3
pubmed: 16403784
Annu Rev Med. 1990;41:277-88
pubmed: 2184730
Amino Acids. 2006 Nov;31(4):359-63
pubmed: 16874467
PLoS One. 2018 Jun 27;13(6):e0198673
pubmed: 29949606
J Adolesc Health. 2008 Nov;43(5):490-7
pubmed: 18848678
Tissue Barriers. 2014 Mar 19;2:e28426
pubmed: 25045600
Food Chem Toxicol. 2019 Oct;132:110653
pubmed: 31265866
Toxicology. 1989 Apr;55(1-2):193-205
pubmed: 2711403
Forensic Sci Int. 2015 Sep;254:118-25
pubmed: 26218406
Parkinsonism Relat Disord. 2013 Sep;19(9):777-82
pubmed: 23706539
Dialogues Clin Neurosci. 2006;8(3):311-21
pubmed: 17117613
Sci Rep. 2019 Jun 28;9(1):9412
pubmed: 31253835
J Neurosci. 1995 May;15(5 Pt 2):4102-8
pubmed: 7751968
PLoS One. 2012;7(1):e30069
pubmed: 22253884
J Med Toxicol. 2012 Sep;8(3):314-21
pubmed: 22782458
Nihon Yakurigaku Zasshi. 2007 May;129(5):354-9
pubmed: 17507772
PLoS One. 2020 May 12;15(5):e0233010
pubmed: 32396581
Drug Alcohol Depend. 2017 May 1;174:70-79
pubmed: 28319752
Neurosci Lett. 2011 Sep 8;502(1):65-9
pubmed: 21803121
Life Sci. 1989;45(21):2025-39
pubmed: 2601563
Forensic Sci Med Pathol. 2017 Sep;13(3):355-358
pubmed: 28656354
Yakugaku Zasshi. 1994 Dec;114(12):950-71
pubmed: 7869236
J Toxicol Pathol. 2015 Jan;28(1):33-6
pubmed: 26023259
J Addict Med. 2014 Jan-Feb;8(1):6-13
pubmed: 24481080
Biochem Pharmacol. 2013 Jun 15;85(12):1848-55
pubmed: 23623752
J Addict Med. 2010 Jun;4(2):74-80
pubmed: 20729975
Rinsho Shinkeigaku. 2017 Mar 28;57(3):95-109
pubmed: 28228623
J Drug Assess. 2013 Mar 26;2(1):106-16
pubmed: 27536444
J Neurochem. 1998 May;70(5):1781-92
pubmed: 9572261
Naunyn Schmiedebergs Arch Pharmacol. 2004 Jan;369(1):23-37
pubmed: 14618296
J Vis Exp. 2016 May 06;(111):
pubmed: 27213495
Prog Neurobiol. 2005 May;76(1):22-76
pubmed: 16011870
Toxicol Pathol. 2011 Jan;39(1):186-212
pubmed: 21189316
Pharmazie. 2016 Jun;71(6):334-6
pubmed: 27455552
J Alzheimers Dis. 2010;20 Suppl 1:S221-38
pubmed: 20182023
Fluids Barriers CNS. 2020 Mar 5;17(1):20
pubmed: 32138786
Neuropathol Appl Neurobiol. 1988 Jan-Feb;14(1):1-17
pubmed: 3374751
Birth Defects Res. 2017 Dec 1;109(20):1640-1648
pubmed: 29251842
Leg Med (Tokyo). 2021 Jul;51:101864
pubmed: 33798967
Eur J Pharmacol. 1997 Feb 26;321(2):181-8
pubmed: 9063686
Planta Med. 2017 Nov;83(16):1256-1263
pubmed: 28675917
Mol Pharm. 2013 May 6;10(5):1473-91
pubmed: 23298398
Brain. 2020 Apr 1;143(4):1127-1142
pubmed: 32293668
Psychopharmacology (Berl). 1994 Oct;116(2):125-9
pubmed: 7862940
Hum Cell. 2005 Mar;18(1):67-72
pubmed: 16130902